Company intelligence / Profile preview
Kyverna Therapeutics
Emeryville, California, United Stateskyvernatx.com ↗
- Ownership
- Public · KYTX
- Development stage
- Phase 2
01
Overview
Kyverna’s lead candidate KYV‑101 has demonstrated a favorable safety profile with no immune effector cell-associated neurotoxicity syndrome reported after infusion in early studies. The company has treated over fifty patients across Europe and the U.S., showing promising tolerability and efficacy signals in autoimmune conditions such as lupus nephritis, myasthenia gravis, multiple sclerosis, stiff person syndrome, and systemic sclerosis. Topline data from pivotal trials are expected between late 2025 and early/mid‑2026.[3][6][8]
- Therapeutic areas
- ImmunologyNeurologyRheumatology
- Modalities
- Autologous CAR T-cell therapy (KYV-101, KYV-102)Allogeneic CAR T-cell therapy (KYV-201)
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Request access →03
Partnerships
Not explicitly listed; notable collaboration with the National Institutes of Health on scientific publications regarding cell therapies for autoimmunity.[8]
04
Financials
- Market cap
- $490.6M
- Total revenue
- $0
- Enterprise value
- $324.2M
Beyond the preview
Go deeper on Kyverna Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kyverna Therapeutics.